Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT

M. Robin, R. Porcher, W. Zinke-Cerwenka, A. van Biezen, L. Volin, G. Mufti, C. Craddock, J. Finke, C. Richard, J. Passweg, A. Peniket, J. Maertens, G. Sucak, T. Gedde-Dahl, A. Vitek, A. Nagler, D. Blaise, D. Beelen, N. Maillard, R. Schwerdtfeger,...

. 2017 ; 52 (2) : 209-215. [pub] 20161107

Language English Country Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18016926
E-resources Online Full text

NLK Free Medical Journals from 1997 to 1 year ago
Freely Accessible Science Journals from 1997 to 1 year ago
ProQuest Central from 2000-01-01 to 1 year ago
Open Access Digital Library from 1997-01-01
Health & Medicine (ProQuest) from 2000-01-01 to 1 year ago

Links

PubMed 27819688
DOI 10.1038/bmt.2016.266
Knihovny.cz E-resources

We report a retrospective analysis of 246 myelodysplastic syndrome (MDS) patients in the EBMT (The European Society for Blood and Marrow Transplantation) database who were transplanted for International Prognostic Scoring System (IPSS) low or intermediate-1 disease. The majority of these patients (76%) were reclassified as intermediate or higher risk according to R-IPSS. The 3-year overall survival (OS) and PFS were 58% and 54%, respectively. In a multivariate analysis, adverse risk factors for PFS were marrow blast percentage (hazard ratio (HR): 1.77, P=0.037), donor/recipient CMV serostatus (donor-/recipient+: HR: 2.02, P=0.011) and source of stem cells (marrow and non-CR: HR: 5.72, P<0.0001, marrow and CR: HR: 3.17, P=0.027). Independent risk factors for OS were disease status at time of transplant and the use of in vivo T-cell depletion (TCD). Patients who did not receive TCD and were transplanted from an unrelated donor had worse OS (HR: 4.08, P<0.0001). In conclusion, 'lower' risk MDS patients have better outcome than those with 'higher risk' after haematopoietic stem cell transplant (HSCT). Selecting the right source of stem cells, a CMV-positive donor for CMV-positive patients and using in vivo TCD results in the best outcome in these patients. More studies are needed to evaluate the role of HSCT in these patients as compared with conventional treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016926
003      
CZ-PrNML
005      
20231109083639.0
007      
ta
008      
180515s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/bmt.2016.266 $2 doi
035    __
$a (PubMed)27819688
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Robin, M $u Hôpital Saint-Louis, Service d'Hématologie-Greffe, Assistance Publique Hôpitaux de Paris, Paris, France.
245    10
$a Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT / $c M. Robin, R. Porcher, W. Zinke-Cerwenka, A. van Biezen, L. Volin, G. Mufti, C. Craddock, J. Finke, C. Richard, J. Passweg, A. Peniket, J. Maertens, G. Sucak, T. Gedde-Dahl, A. Vitek, A. Nagler, D. Blaise, D. Beelen, N. Maillard, R. Schwerdtfeger, T. de Witte, N. Kroger,
520    9_
$a We report a retrospective analysis of 246 myelodysplastic syndrome (MDS) patients in the EBMT (The European Society for Blood and Marrow Transplantation) database who were transplanted for International Prognostic Scoring System (IPSS) low or intermediate-1 disease. The majority of these patients (76%) were reclassified as intermediate or higher risk according to R-IPSS. The 3-year overall survival (OS) and PFS were 58% and 54%, respectively. In a multivariate analysis, adverse risk factors for PFS were marrow blast percentage (hazard ratio (HR): 1.77, P=0.037), donor/recipient CMV serostatus (donor-/recipient+: HR: 2.02, P=0.011) and source of stem cells (marrow and non-CR: HR: 5.72, P<0.0001, marrow and CR: HR: 3.17, P=0.027). Independent risk factors for OS were disease status at time of transplant and the use of in vivo T-cell depletion (TCD). Patients who did not receive TCD and were transplanted from an unrelated donor had worse OS (HR: 4.08, P<0.0001). In conclusion, 'lower' risk MDS patients have better outcome than those with 'higher risk' after haematopoietic stem cell transplant (HSCT). Selecting the right source of stem cells, a CMV-positive donor for CMV-positive patients and using in vivo TCD results in the best outcome in these patients. More studies are needed to evaluate the role of HSCT in these patients as compared with conventional treatment.
650    _2
$a alografty $7 D064591
650    _2
$a refrakterní anemie s nadbytkem blastů $x mortalita $x terapie $7 D000754
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a registrace $7 D012042
650    _2
$a rizikové faktory $7 D012307
650    _2
$a míra přežití $7 D015996
655    _2
$a časopisecké články $7 D016428
700    1_
$a Porcher, R $u Team METHODS, Epidemiology and Statistics Sorbonne Paris Cité Research Centre UMR 1153, Inserm, Paris Descartes University, Paris, France. AP-HP, Hôpital Hôtel-Dieu, Centre d'Épidémiologie Clinique, Paris, France.
700    1_
$a Zinke-Cerwenka, W $u Medical University of Graz, Hematology Department, Graz, Austria.
700    1_
$a van Biezen, A $u EBMT Data Office, Leiden, The Netherlands.
700    1_
$a Volin, L $u Helsinki University Central Hospital, Hematology Department, Helsinki, Finland.
700    1_
$a Mufti, G $u King's College Hospital, Hematology Department, London, UK.
700    1_
$a Craddock, C., $u Queen Elizabeth Hospital, Hematology Department, Birmingham, UK. $d 1957- $7 xx0309755
700    1_
$a Finke, J $u Universitatsklinikum, Hematology Department, Freiburg, Germany.
700    1_
$a Richard, C $u Hospital de Valdecilla, Hematology Department, Santander, Spain.
700    1_
$a Passweg, J $u University Hospital, Hematology Department, Basel, Switzerland.
700    1_
$a Peniket, A $u Oxford University Hospital NHS Trust, Hematology Department, Oxford, UK.
700    1_
$a Maertens, J $u Uz Gasthuisberg, Hematology Department, Leuven, Belgium.
700    1_
$a Sucak, G $u Gazi University, Hematology Department, Ankara, Turkey.
700    1_
$a Gedde-Dahl, T $u Rikshospitalet, Oslo, Norway.
700    1_
$a Vitek, A $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Nagler, A $u Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.
700    1_
$a Blaise, D $u IPC, Hematology Department, Marseille, France.
700    1_
$a Beelen, D $u University Hospital, Hematology Department, Essen, Germany.
700    1_
$a Maillard, N $u CHU, Hematology Department, Poitiers, France.
700    1_
$a Schwerdtfeger, R $u Center of Bone Marrow Transplantation, Wiesbaden, Germany.
700    1_
$a de Witte, T $u University Medical Centre St Radboud, Hematology Department, Nijmegen, Netherlands.
700    1_
$a Kroger, N $u University Hospital, Hematology Department, Hamburg, Germany.
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 52, č. 2 (2017), s. 209-215
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27819688 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20231109083634 $b ABA008
999    __
$a ok $b bmc $g 1300550 $s 1013766
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 52 $c 2 $d 209-215 $e 20161107 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
LZP    __
$a Pubmed-20180515

Find record

Citation metrics

Archiving options